Compile Data Set for Download or QSAR
Report error Found 81 Enz. Inhib. hit(s) with all data for entry = 12698
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720759(5-chloro-3-[3-chloro-6-[(3S,5R)-3,5-dimethylpipera...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720757(5-chloro-3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720716(N-methyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720761(3-[4-chloro-6-(3-piperidyl)-2-pyridyl]-5-isopropox...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720762(5-chloro-3-[6-(3,3,5,5-tetramethylpiperazin-1-yl)-...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720703(5-chloro-3-[6-[(3R)-3-piperidyl]-2-pyridyl]pyrazol...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720755(5-chloro-3-[4-chloro-6-[(3S,5R)-3,5-dimethylpipera...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720754(5-chloro-3-[6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720753(5-chloro-3-[6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720752(3-[4-chloro-6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720751(3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720750(3-[4-chloro-6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720738(5-chloro-3-(6-piperazin-1-yl-2-pyridyl)pyrazolo[1,...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720749(3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720748(3-[6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4-fluoro...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720747(3-[4-chloro-6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720746(3-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720745(3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720742(3-(6-(5-chloropyrazolo[1,5-a]pyridin-3-yl)pyridin-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720740(5-chloro-3-(4-fluoro-6-piperazin-1-yl-2-pyridyl)py...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720739(5-chloro-3-(4-chloro-6-piperazin-1-yl-2-pyridyl)py...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720737(3-(4-chloro-6-piperazin-1-yl-2-pyridyl)-5-(trifluo...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720769(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720777(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720776(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720775(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720774(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720773(2-cyano-N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720772(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720771(4-cyano-N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720770(3-cyano-N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720758(3-[4-chloro-6-(3-piperidyl)-2-pyridyl]-N-methyl-py...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720768(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720767(5-chloro-3-(6-((3S,5R)-3,4,5-trimethylpiperazin-1-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720766((S)-3-(6-(3-methylpiperazin-1-yl)pyridin-2-yl)pyra...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720765((R)-3-(6-(3-methylpiperazin-1-yl)pyridin-2-yl)pyra...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720764(2-(methylsulfonamido)-N-(3-(6-(piperidin-3-yl)pyri...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720763(2-(methylsulfonyl)-N-(3-(6-(piperidin-3-yl)pyridin...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720760(5-chloro-3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720706(3-[6-(3-piperidyl)-2-pyridyl]-5-(trifluoromethyl)p...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720713(3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5-a]pyridi...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720714(5-cyclopropyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazol...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720717(N-ethyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720718(3-(methylsulfonamido)-N-(3-(6-(piperidin-3-yl)pyri...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720736(3-(6-piperazin-1-yl-2-pyridyl)-5-(trifluoromethyl)...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720709(5-isopropoxy-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720707(5-methoxy-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720724(3-(4-chloro-6-(piperidin-3-yl)pyridin-2-yl)pyrazol...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720725(3-[5-chloro-6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandPNGBDBM720705(5-methyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 81 total ) | Next | Last >>
Jump to: